AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus
A combination of the company’s breast cancer drug Etcamah did not delay worsening of the disease enough to meet the SERENA-4 late-stage trial’s main goal, AstraZeneca said. AstraZeneca, however, said progression-free survival improved numerically. Etcamah is a once-daily pill that breaks down the estrogen receptor many breast cancers use to grow and is already approved … Read more